IQVIA: Global Drug Use Report 2022

Despite the uncertainty created by the global pandemic over the past two years, the outlook for global pharmaceutical spending has become clearer as healthcare systems and policymakers in both advanced and emerging economies face more predictable challenges and opportunities. Healthcare has demonstrated remarkable resilience during COVID-19, but challenges remain—and evidence-based decision-making is more important than ever.

The biggest driver of drug spending over the next five years is expected to be global COVID-19 vaccination, which is unprecedented because of the number of people vaccinated and the speed at which it is expected to be achieved, as well as the frequent subsequent booster shots. But even leaving the pandemic aside, global drug spending continues to be driven by innovation, offset by cost reductions for generics and biosimilars.

The report quantifies the impact of these dynamics and examines drug spending and use in 2021 and outlooks to 2026 globally as well as for specific therapeutic sub-branches and countries, laying the foundation for a meaningful discussion about the value, cost, and role of medicines in the context of overall healthcare spending over the next five years.

Key findings

• The global pharmaceutical market is expected to grow at a CAGR of 3-6% by 2026.
• Drug utilization and spending trends are negatively impacted by the COVID-19 pandemic, but will be offset by increased spending on related vaccines and therapeutics.
• By 2026, global pharmaceutical spending will be boosted by strong growth in the pharmaceutical market, offset by slower growth in developed markets due to the loss of exclusivity of originator brands.
• A total of 300 new drugs are expected to be launched in the next five years to 2026, significantly higher than the average level of the past decade, with a focus on specialty drugs, niche drugs and drugs for rare diseases.
• New drug launches over the next five years will generate $196 billion in new spending, mostly offset by reduced brand spending.
• The two leading therapeutic areas globally – oncology and immunology – will grow at CAGRs of 9-12% and 6-9% respectively through 2026, driven by significant growth in new therapies and drug use, as well as the impact of biosimilars.
• In neurology, many new drugs hold promise for treating a range of conditions, including novel migraine treatments, rare neurological disorders, and treatments for Alzheimer’s and Parkinson’s diseases.

The PDF version will be shared on 199IT Knowledge Planet, just scan the QR code below!